OMEGA THERAPEUTICS INC (OMGA) Stock Price, Forecast & Analysis
USA - NASDAQ:OMGA - US68217N1054 - Common Stock
OMGA Key Statistics, Chart & Performance
The current stock price of OMGA is 0.1426 USD. In the past month the price decreased by -71.98%. In the past year, price decreased by -96.68%.
OMGA Latest News, Press Relases and Analysis
OMGA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.61B | ||
| AMGN | AMGEN INC | 15.54 | 182.96B | ||
| GILD | GILEAD SCIENCES INC | 15.35 | 156.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 109.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.6 | 79.20B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 889.57 | 59.47B | ||
| INSM | INSMED INC | N/A | 43.01B | ||
| NTRA | NATERA INC | N/A | 30.77B | ||
| BIIB | BIOGEN INC | 10.13 | 24.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.09 | 21.60B | ||
| INCY | INCYTE CORP | 15.91 | 19.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.15B |
Related stock screener links
About OMGA
Company Profile
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Company Info
OMEGA THERAPEUTICS INC
140 First Street, Suite 501
Cambridge MASSACHUSETTS US
CEO: Mahesh Karande
Employees: 94
Phone: 16179494360
OMEGA THERAPEUTICS INC / OMGA FAQ
What does OMEGA THERAPEUTICS INC do?
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 93 full-time employees. The company went IPO on 2021-07-30. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The firm designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Can you provide the latest stock price for OMEGA THERAPEUTICS INC?
The current stock price of OMGA is 0.1426 USD. The price decreased by -10.82% in the last trading session.
Does OMGA stock pay dividends?
OMGA does not pay a dividend.
What is the ChartMill rating of OMEGA THERAPEUTICS INC stock?
OMGA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for OMEGA THERAPEUTICS INC?
OMEGA THERAPEUTICS INC (OMGA) has a market capitalization of 7.90M USD. This makes OMGA a Nano Cap stock.
Who owns OMEGA THERAPEUTICS INC?
You can find the ownership structure of OMEGA THERAPEUTICS INC (OMGA) on the Ownership tab.
OMGA Technical Analysis
OMGA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OMGA. Both the profitability and financial health of OMGA have multiple concerns.
OMGA Financial Highlights
Over the last trailing twelve months OMGA reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 36.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.86% | ||
| ROE | -633.21% | ||
| Debt/Equity | 1 |
OMGA Forecast & Estimates
7 analysts have analysed OMGA and the average price target is 13.26 USD. This implies a price increase of 9198.74% is expected in the next year compared to the current price of 0.1426.
For the next year, analysts expect an EPS growth of 34.35% and a revenue growth 233.18% for OMGA